Trials / Terminated
TerminatedNCT00401310
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT). This test allows measurement of a specific functional deficit and subsequent recovery correlating with the specific area of stroke in the brain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comparator: Placebo | Placebo IV infusions 1hr/daily over 7 days. |
| DRUG | Comparator: MK0724 | MK0724 8 mg/kg/hr 1 hr/daily over 7 days. |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2006-11-20
- Last updated
- 2015-07-22
Source: ClinicalTrials.gov record NCT00401310. Inclusion in this directory is not an endorsement.